Artal Group’s Praxis Precision Medicines PRAX Stock Holding History

Artal Group’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-80,000	Closed	-$2.86M	–	138
2022 Q4	$2.86M	Hold	80,000	–	–	0.16%	77
2022 Q3	$2.72M	Hold	80,000	–	–	0.12%	81
2022 Q2	$2.94M	Hold	80,000	–	–	0.16%	82
2022 Q1	$12.3M	Hold	80,000	–	–	0.51%	44
2021 Q4	$23.6M	Hold	80,000	–	–	0.64%	41
2021 Q3	$22.2M	Hold	80,000	–	–	0.5%	51
2021 Q2	$21.9M	Buy	80,000 +30,000	+60%	+$10.7M	0.45%	50
2021 Q1	$24.6M	Hold	50,000	–	–	0.43%	51
2020 Q4	$41.3M	Buy	+50,000	New	+$29.2M	0.89%	30

Other funds holding PRAX

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Artal Group's PRAX Position: Q1 2023 in Review

Artal Group sold out of Praxis Precision Medicines (PRAX) in Q1 2023, closing a stake of 80,000 shares — an estimated $2.86M sold.

Artal Group first reported a position in PRAX in Q4 2020 and held it in 9 quarters. The position peaked at $41.3M in Q4 2020. 86 funds tracked by Wall St. Rank hold PRAX as of Q1 2023.

Artal Group reported no remaining Praxis Precision Medicines position as of Q1 2023 after selling out during the quarter.
Artal Group sold 80,000 Praxis Precision Medicines shares in Q1 2023, an estimated $2.86M.
Artal Group first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 9 quarters.
Artal Group's Praxis Precision Medicines position peaked at $41.3M in Q4 2020.
86 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.